首页> 美国卫生研究院文献>The Mental Health Clinician >Medication management of bipolar disorder during the reproductive years
【2h】

Medication management of bipolar disorder during the reproductive years

机译:生殖年躁郁症的药物管理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The management of bipolar disorder during reproductive years is a challenge to both patient and clinician. The rapidly changing landscape of medical literature, newly available medications, and implementation of the Pregnancy and Lactation Labeling Final Rule by the Food and Drug Administration can be dizzying. This article serves as a brief, practical guide on the use of medications for the treatment of bipolar disorder before, during, and immediately after pregnancy. Special focus is devoted to the risk-benefit analysis of using potentially teratogenic medications during pregnancy. Availability and appropriateness of various contraceptive methods and folic acid supplementation in combination with mood stabilizers is also addressed. Every clinician managing bipolar disorder in adult women should be knowledgeable of family planning resources and what to do in the setting of unintended pregnancy.
机译:生殖年期间躁郁症的管理对患者和临床医生都是一个挑战。医学文献,新近可用的药物以及美国食品和药物管理局对怀孕和哺乳标记最终规则的执行情况瞬息万变,这可能令人头晕。本文是有关在妊娠前,妊娠中和妊娠后使用药物治疗躁郁症的简要实用指南。特别关注致力于在怀孕期间使用潜在致畸药物的风险效益分析。还讨论了各种避孕方法和叶酸补充剂与情绪稳定剂的组合的适用性和适用性。每位处理成年女性双相情感障碍的临床医生都应了解计划生育资源以及在意外怀孕情况下应采取的措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号